- Research Resources
- Conferences & Seminars
- MD Anderson at ESMO
- ESMO Program
MD Anderson has numerous presentations throughout the ESMO program. Note: All times are listed in CEST (Central European Summer Time).
MD Anderson has numerous presentations throughout the ESMO program. Note: All times are listed in CEST (Central European Summer Time).
Oral presentations
Friday, October 17
Abstract 923MO: First results from a Phase I trial of SNV1521, a next generation, CNS-penetrant, PARP1-selective inhibitor in patients (pts) with molecularly selected advanced solid tumors
Abstract 924MO: First data disclosure of the first-in-class DNA polymerase theta inhibitor, ART6043, as monotherapy and in combination with olaparib, in patients with molecularly-selected advanced solid tumors
16:00¨C17:30 (4¨C5:30 p.m.)
Heidelberg Auditorium, Hall 6.2
Presenter of Both Abstracts:
Saturday, October 18
Talk: Emerging medical therapies for brain and leptomeningeal melanoma metastases
08:30¨C9:45
Heidelberg Auditorium, Hall 6.2
Presenter and Session Chair:
08:30¨C9:30
Bremen Auditorium, Hall 6.2
Presenter:
Talk: Clinical advances in targeting chromosomal instability
08:30¨C10:00
Dortmund Auditorium, Hall 7.1a
Presenter:
Talk: Can we improve drug development in colorectal cancer? Turning failure into success
08:30¨C10:00
Hanover Auditorium, Hall 7.2c
Presenter:
Abstract 113MO: Multimodal molecular investigation of >1,000 rare cancer patients (pts) reveals key tumor states and germline susceptibility genetics
08:30¨C10:00
Cologne Auditorium, CityCube A
Presenter:
Abstract 1705O: LITESPARK-015: Belzutifan in advanced pheochromocytoma and paraganglioma
10:15¨C11:45
Karlsruhe Auditorium, Hall 5.2
Presenter:
Sunday, October 19
Abstract 1250MO: Outcomes of patients with chronic myeloid leukemia receiving second-line therapy
08:30¨C10:00
Solingen Auditorium, Hall 23
Presenter:
Talk: ADC and PARP/DDR inhibitor combinations
08:30¨C10:00
Nuremberg Auditorium, Hall 5.2
Presenter:
Talk: RT for angiosarcoma: Sequencing therapies
10:15¨C11:30
Bremen Auditorium, Hall 6.2
Presenter and Session Chair:
Abstract 729MO: Circulating tumor (ct) DNA analysis of BRAF V600E dynamics and changes in genomic landscape in patients (pts) with first-line (1L) BRAF V600E-mutant metastatic colorectal cancer (mCRC) treated in BREAKWATER
14:45¨C16:15 (2:45¨C4:15 p.m.)
Cologne Auditorium, CityCube A
Presenter:
Talk: Resectable NSCLC without oncogene addiction
14:45¨C16:15 (2:45¨C4:15 p.m.)
Hanover Auditorium, Hall 7.2c
Presenter and Session Chair:
Abstract 920O: Safety and efficacy of first-in-class, YAP/TEAD inhibitor, VT3989 in refractory pleural and non-pleural mesothelioma: A Phase I/II study
16:30¨C18:00 (4:30¨C6 p.m.)
Hanover Auditorium, Hall 7.2c
Presenter:
Abstract 1326MO: RTOG 1016 long-term update and smoking analysis
16:30¨C18:00 (4:30¨C6 p.m.)
Cologne Auditorium, CityCube A
Presenter:
Monday, October 20
Talk: Aggressive variant prostate cancer
08:30¨C10:00
Hanover Auditorium, Hall 7.2c
Presenter and Session Chair:
Talk: TCR mimic bispecifics?
10:15¨C11:45
Bonn Auditorium, Hall 7.1c
Presenter and Session Chair: Timothy Heffernan, Ph.D.
Talk: Rediscovering CTLA-4 blockade
16:30¨C18:00 (4:30¨C6 p.m.)
Nuremberg Auditorium, Hall 5.2
Presenter:
Posters
Posters are displayed in Hall 25 on a rotating schedule, which will be released by ESMO ahead of the meeting. Presenters will be present from 12:00 to 12:45 the day of their assigned presentation day.
Biliary tract cancer, incl. cholangiocarcinoma
81P: Survival and safety of tinengotinib in pooled patients with advanced, fibroblast growth factor receptor (FGFR) inhibitor refractory/relapsed cholangiocarcinoma (CCA)
Presenter:
94P: The association between tumor immunogenomic features and first line (1L) therapeutic outcomes in advanced biliary tract cancer (BTC)
Presenter: Nakul Shah, M.D.
Biomarkers & translational research (agnostic)
120P: Dynamic evolution of precision oncology decision support for clinical care
Presenter: Amber Johnson, Ph.D.
123P: Cancer signal origin (CSO) prediction in cancer of unknown primary (CUP) syndrome (CRONUS) using circulating tumor DNA (ctDNA)
Presenter:
Breast cancer, early stage
303P: Biosimilar tastuzumab (T) and cardiotoxicity in patients with early-stage breast cancer (BC)
Presenter:
413P: Decision regret in older breast cancer survivors
Presenter: Sharon Giordano?
Breast cancer, metastatic
520P: Long-term safety and efficacy of first-line atirmociclib + letrozole for the treatment of patients with HR+/HER2? metastatic breast cancer (mBC)
Presenter:
567P: Accumulation of CD38 in hybrid epithelial/mesenchymal cells promotes immune remodeling and metastasis in breast cancer
Presenter: Tanvi Visal
605P: Outcomes of subsequent antibody drug conjugate (ADC) regimen in ADC-resistant HER2 low metastatic breast cancer
Presenter: Vicente Valero?
CNS tumors
712TiP: Concurrent intrathecal (IT) and intravenous (IV) nivolumab (nivo) and relatlimab (rela) for melanoma patients (pts) with leptomeningeal disease (LMD)
Presenter: Isabella Glitza
Colorectal cancer
737P: Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic colorectal cancer (mCRC): final analysis of DESTINY-CRC02, a randomized, Phase II trial
Presenter: Kanwal Raghav
799P: Fruquintinib plus tislelizumab in microsatellite stable metastatic colorectal cancer: Results from a Phase Ib/II study
Presenter: Arvind Dasari?
809P: Safety profile associated with first-line (1L) encorafenib plus cetuximab (EC) ¡À mFOLFOX6 and chemotherapy (chemo) ¡À bevacizumab (bev) in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) (BREAKWATER)
Presenter:
893eP: Boarding time as a predictor of short-term mortality in colorectal cancer patients visiting the emergency department
Presenter: Patricia Brock
909eTiP: Open-label Phase II trial of AMB-05X for patients with ctDNA(+) colorectal cancer after curative-intent treatment
Presenter: Michael LaPelusa
Developmental Therapeutics
939P: Phase I, dose-escalation study evaluating safety & efficacy of trastuzumab deruxtecan (T-DXd) in combination with ATR inhibitor (AZD6738, ceralasertib) in advanced solid tumors with HER2 expression (DASH)
Presenter: Kanwal Raghav
962P: Precemtabart tocentecan (M9140), an anti-CEACAM5 ADC with exatecan payload, in patients with metastatic colorectal cancer: Updated clinical data from the Phase I PROCEADE-CRC-01 study
Presenter:
971P: Efficacy and safety of larotrectinib in patients with TRK fusion cancer who had a long-term response
Presenter: David Hong?
977P: DS3201, an EZH1/2 inhibitor, with ipilimumab in patients with refractory genitourinary tumors
Presenter: Sangeeta Goswami
983P: Phase I/II clinical study of a first-in-class antisense oligonucleotide (TTX-MC138) therapeutic against advanced solid tumors of multiple tissue origins
Presenter: Siqing Fu
986P: Phase I study of NovoTTF-100L(P) in combination with chemotherapy in patients with predominant hepatic metastatic colorectal cancer
Presenter: Siqing Fu
987P: Phase i study of tumor treating fields (TTFS) with cabozantinib or with nab-paclitaxel and pembrolizumab in patients with advanced solid tumors involving the abdomen or thorax
Presenter: Apostolia Maria Tsimberidou
990P: Concordance analysis of DNA and RNA profiling: Results of the MD Anderson IMPACT2 study in precision oncology
Presenter: Stephanie Schmidt
Gynaecological cancers
1112P: Phase II randomized controlled trial of everolimus and letrozole with or without ribociclib in advanced/recurrent endometrial cancer (EC)
Presenter: Jeffrey How
1117P: Durvalumab plus carboplatin/paclitaxel followed by durvalumab for endometrial cancer: Tumour mutational burden-high subpopulation efficacy analyses from the DUO-E trial
Presenter: Shannon Westin
Haemtaological malignancies
1284P: CDK9 inhibition enhances venetoclax activity and prolongs survival in a T-PLL patient-derived xenograft model
Presenter: Claudia Kettlun Leyton
Head and neck, excluding thyroid
1350P: Immuno-chemotherapy alone for laryngeal cancer: ICoLP Phase II Trial with >2-year follow-up
Presenter: Renata Ferrarotto
1407P: Using liquid biopsies to classify adenoid cystic carcinoma into clinically relevant subtypes
Presenter: Simon Heeke
Investigational immunotherapy
1526P: Unexpected improvements in survival among patients treated with immune checkpoint inhibitors during the COVID-19 pandemic are strongly associated with SARS-CoV-2 mRNA vaccination
Presenter: Adam Grippin
1564P: First-in-human, Phase I study of BGB-26808 (hematopoietic progenitor kinase 1 [HPK1] inhibitor) ¡À tislelizumab (TIS; anti-PD-1) in advanced solid tumors (STs)
Presenter: Aung Naing
Melanoma and other skin tumors
1612P: Characterization of tumor and peripheral biomarkers in patients (pts) with resectable melanoma (MEL) treated with adjuvant nivolumab + relatlimab (NIVO + RELA) or NIVO alone in RELATIVITY-098
Presenter:
1619P: Pooled outcomes with first-line nivolumab + relatlimab (NIVO + RELA) in patients (pts) with advanced melanoma (MEL)
Presenter:
1659P: Updated pathologic responses from a pilot Phase II Trial of neoadjuvant immunotherapy for stage ii-iv resectable cutaneous squamous cell carcinoma of the head and neck (CSCC-HN)
Presenter: Moran Amit
NSCLC, metastatic
2020P: Circulating tumor DNA (ctDNA) analysis following zongertinib treatment (tx) in patients (pts) with human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC): Phase Ia/Ib Beamion LUNG-1 study
Presenter: John Heymach
Pancreatic cancer
2248P: Integrated analysis of KRAS mutations and MTAP loss in pancreatic cancer reveals potential for combined blockade of KRAS and PRMT5
Presenter: Jordi Rodon?
Prostate cancer
2467P: Higher circulating tumor DNA levels in chemo-experienced mCRPC patients serve as a poor prognostic marker for checkpoint inhibitors (CI) or chemotherapy: A post hoc analysis of CM 650
Presenter: Padmanee Sharma
Renal cancer
2631P: Unmet needs & disparities in kidney cancer (KC): International Kidney Cancer Coalition (IKCC) global patient survey (GPS)
Presenter: Eric Jonasch
Sarcoma
2750eP: Molecular tumor boards (MTB) as a tool for Phase I and II clinical trial (CT) selection in sarcoma: A 5-Year retrospective study
Presenter: Carlos Torrado Martin
SCLC
2785P: Real-world treatment patterns and progression-free survival from first-line chemoimmunotherapy in patients with extensive-stage small cell lung cancer in the US
Presenter: Xiuning Le
Urothelial cancer
3094P: Validation of prognostic scores for advanced urothelial cancer (aUC) for enfortumab vedotin/pembrolizumab (EVP): Analysis of the UNITE study
Presenter: Cindy Jiang
Give Now
Your gift will help make a tremendous difference.
Research Areas
Find out about the four types of research taking place at MD Anderson.
Subscribe
Get the latest information on our cancer breakthroughs.?